Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide)—known as “AC chemotherapy”—and had fewer side effects. The regimens were tested in patients with stage 1 to 3 breast
Progression-free survival (the length of time without a worsening of their breast cancer) was longer with Verzenio: 28.2 months for women taking the Verzenio combination compared with 14.8 months for women taking the placebo combination 55.4% of women taking the Verzenio combination had either a co...
While the "jury is still out" regarding the efficacy ofCytoxan, mitoxantrone seems to be an important addition in the care of patients with progressive multiple sclerosis. For those patients with relapsing forms of MS, all 3 immunomodulating therapies provide a substantial benefit in relapse reductio...
Experimentation is ongoing to see if new combinations may work better than established treatments. For example, aNew England Journal of Medicinestudyof more than 500 CLL patients found that combination therapy of ibrutinib and rituximab may be more effective than FCR (aprogression-free survival rateof...